Robert LeBoyer
Stock Analyst at Noble Capital Markets
(2.37)
# 2,508
Out of 4,944 analysts
18
Total ratings
43.75%
Success rate
13.28%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding | Reiterates: Outperform | $70 | $61.57 | +13.69% | 2 | Mar 20, 2025 | |
| NTRB Nutriband | Initiates: Outperform | $13 | $6.66 | +95.20% | 1 | Jan 22, 2025 | |
| GOVX GeoVax Labs | Maintains: Outperform | $6 → $10 | $0.74 | +1,253.18% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $60 | $4.41 | +1,260.54% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $11.68 | +413.70% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $2.60 | +284.62% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $1.60 | +775.00% | 1 | Feb 21, 2023 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $1.03 | +676.70% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $120 | $0.57 | +20,791.36% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $12.51 | - | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $10.56 | +13.64% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9,900,000 | $6.79 | +145,802,550.96% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $14.03 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $3.89 | +285.60% | 2 | Mar 8, 2018 |
Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $61.57
Upside: +13.69%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $6.66
Upside: +95.20%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $6 → $10
Current: $0.74
Upside: +1,253.18%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $4.41
Upside: +1,260.54%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $11.68
Upside: +413.70%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $2.60
Upside: +284.62%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $1.60
Upside: +775.00%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.03
Upside: +676.70%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $0.57
Upside: +20,791.36%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $12.51
Upside: -
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $10.56
Upside: +13.64%
Aug 24, 2020
Initiates: Buy
Price Target: $9,900,000
Current: $6.79
Upside: +145,802,550.96%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $14.03
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $3.89
Upside: +285.60%